A5 Laboratories Inc. - FORM 8-K - June 23, 2010
| Attached files | ||||||
| File | Filename | |||||
|---|---|---|---|---|---|---|
| EX-10.1 - CRO ASSET ACQUISITION AGREEMENT - A5 Laboratories Inc. | exhibit10-1.htm | |||||
| EX-10.2 - INTERFERON ASSET ACQUISITION AGREEMENT - A5 Laboratories Inc. | exhibit10-2.htm | |||||
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 18, 2010
A5 LABORATORIES INC.
(Exact name of registrant as specified in its charter)
| Nevada | 333-138927 | 20-5277531 |
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer |
| incorporation) | Identification No.) |
| 10300 Chemin de la Cote-De-Liesse, Lachine, Quebec | H8T 1A3 |
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code | (514) 420-0333 |
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e -4(c))
Item 1.01 Entry into Material Definitive Agreement
On June 18, 2010 A5 Laboratories Inc. (“we”, “us”, “our”) entered into a CRO asset acquisition agreement and an Interferon asset acquisition agreement with Vida Nutra Pharma Inc. Pursuant to the terms of the agreements, upon the closing of the agreements, we will acquire certain hard assets related to the business of contract research activities as well as naturally produced interferon technology in exchange for options to acquire 1,000,000 shares of our common stock at a price of $0.001 per share for a period of 60 months from the date of closing. Vida Nutra Pharma Inc., is a company controlled by our sole director and officer, Richard Azani.
Due to conditions precedent to closing and the risk that these conditions precedent will not be satisfied, there is no assurance that we will complete the acquisitions as contemplated in the agreements.
Full copies of the agreements are filed as Exhibits 10.1 and 10.2.
Item 9.01 Financial Statements and Exhibits
| 10.1 | CRO Asset Acquisition Agreement dated June 18, 2010 |
| 10.2 | Interferon Asset Acquisition Agreement dated June 18, 2010 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
A5 LABORATORIES INC.
/s/ Richard Azani
Richard Azani
President and
Director
Date: June 23, 2010
User Contributions:
Comment about this document or add new information about this topic:
This web site and associated pages are not associated with, endorsed by, or sponsored by A5 Laboratories Inc. and has no official or unofficial affiliation with A5 Laboratories Inc.
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
